Buprenorphine Sublingual Tablets Recalled for Manufacturing Quality Deviations
Sun Pharmaceutical recalls 12,336 bottles of Buprenorphine 8 mg sublingual tablets (Lot DND1515A) due to Good Manufacturing Practice deviations identified during manufacturing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary precautionary recall. The rubric identifies voluntary precautionary recalls as Moderate severity. No illnesses, injuries, or adverse events are documented in the source.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling 12,336 bottles of Buprenorphine 8 mg sublingual tablets due to Good Manufacturing Practice (CGMP) deviations identified during the manufacturing process. The affected lot is DND1515A with an expiration date of August 2024. Buprenorphine is a prescription opioid medication used to treat opioid use disorder.
The CGMP deviations were identified by the manufacturer, which voluntarily initiated this recall on May 3, 2023. The product was distributed to 19 distributors across the United States. The recall was terminated on January 9, 2024.
Patients currently taking buprenorphine should verify their medication lot number and contact their healthcare provider or pharmacist if they possess the recalled lot. Healthcare providers and dispensing pharmacies should verify whether their patients or inventory includes the recalled lot DND1515A and provide appropriate guidance to affected patients.
The recalled product
- Product
- BUPRENORPHINE (BUPRENORPHINE)
- Brand
- BUPRENORPHINE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Prescription Opioid
- Hazard
- Affected units
- 12,336
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: DND1515A
- Exp 08/24
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPRENORPHINE
- ModerateTeva Recalls Buprenorphine Transdermal Patches for Stability Failures
FDA (Drugs) · 2020-10-07
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09